| June 1 |
FDA and International Consortium Report New Data on Drug-Induced Liver Injury |
| June 1 |
Genentech Announces Full Results from First Phase III Study of Avastin in Early-Stage Colon Cancer |
| June 1 |
Allos Therapeutics Reports Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate at 45th ASCO Annual Meeting |
| June 1 |
A.P. Pharma Presents APF530 Phase 3 Data at Annual Meeting of the American Society of Clinical Oncology |
| June 1 |
Antigenics Presents Positive Oncophage Interim Survival Data at ASCO |
| June 1 |
Gemin X Announces Positive Results in Small Cell Lung Cancer from Phase 1b Trial of Obatoclax at Annual Meeting of the American Society of Clinical Oncology |
| June 1 |
Exelixis Reports Encouraging Phase 1 Data to Be Presented at ASCO for XL228, a Multi-Targeted Inhibitor of Key Cancer Signaling Kinases |
| June 1 |
ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented at ASCO |
| June 1 |
Calistoga Pharmaceuticals' CAL-101, an Oral Delta Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Clinical Activity in Patients with Hematologic Cancers |
| June 1 |
In Clinical Trials VELCADE (Bortezomib) for Injection as a Foundation of Therapy Continues to Deliver Significant Response Rates in Previously Untreated Multiple Myeloma Patients |
| June 1 |
ZymoGenetics Reports Encouraging Phase 2 Results in Renal Cell Cancer for IL-21 with Nexavar |
| June 1 |
Synta Pharmaceuticals Announces Presentation of Preliminary Results of Phase 3 SYMMETRY Trial of Elesclomol in Metastatic Melanoma at ASCO 2009 |
| June 1 |
Exelixis and BMS Report Phase 2 Data to Be Presented at ASCO for XL184 in Patients with Previously Treated Glioblastoma Multiforme |
| June 1 |
Data Presented on Two Novel Millennium Investigational Oncology Drugs at ASCO |
| June 1 |
Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate) Phase II Data at ASCO Annual Meeting |
| June 1 |
Celldex Therapeutics Announces CDX-1307 Clinical Data at 45th Annual ASCO Meeting |
| June 1 |
BioLineRx Announces Positive Preliminary Results From the Phase I/II Trial of BL-1040, the First Injectable Device Addressing Pathological Cardiac Remodeling |
| June 1 |
Enzon Presents Clinical Data from HIF-1 Alpha Antagonist Study at ASCO |
| June 1 |
ASCO Presentations Highlight Findings from Clinical Trials with ArQule's c-MET Inhibitor, ARQ 197 |
| June 1 |
Medarex Announces Efficacy Data in Cancer Patients Treated with Investigational Anti-PD-1 Antibody at American Society of Clinical Oncology Annual Meeting |
| June 1 |
Seattle Genetics Reports Data from a Weekly Dosing Phase I Clinical Trial of SGN-35 in Lymphoma |
| June 1 |
StemCells, Inc. to Present Phase I Clinical Trial Results at the 12th International Congress on NCL |
| June 1 |
Alder Biopharmaceuticals Presents Results From Phase 1 Trial of ALD518 in Advanced Cancer at American Society of Clinical Oncology Annual Meeting |
| June 2 |
Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer |
| June 2 |
Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation |
| June 2 |
Sunesis Pharmaceuticals Presents Voreloxin Clinical Data at the American Society of Clinical Oncology 2009 Annual Meeting |
| June 2 |
Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors |
| June 2 |
Imotuzumab Demonstrates Efficacy in Randomized Head & Neck Cancer Study Without the Toxicities Associated with Other EGFR Drugs |
| June 2 |
Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT Phase 3 Clinical Program |
| June 2 |
AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting |
| June 2 |
Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel |
| June 2 |
Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients |
| June 2 |
Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting |
| June 2 |
Data from Enzo Therapeutics' Phase II Study of Crohn's Disease Presented at Prestigious Gastroenterology Conference |
| June 2 |
GSK's Pazopanib Significantly Delays Tumor Progression in Patients with Advanced Kidney Cancer |
| June 2 |
New Phase III NasalFent data reinforce superiority over the standard of care for breakthrough cancer pain |
| June 2 |
Argos Therapeutics Presents Positive Transplantation and Immunosuppression Data for Soluble CD83 at the American Transplant Congress |
| June 2 |
AEterna Zentaris Partner Keryx Reports Positive Phase 2 Data for Perifosine (KRX-0401) in Colon and Kidney Cancer at ASCO Meeting |
| June 2 |
Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions |
| June 2 |
AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances |
| June 2 |
FDA Advisory Panel Recommends Approval of the Sedayst System |
| June 2 |
Clinical Data, Inc. Announces Positive Results from Second Phase III Trial of Vilazodone for Depression |
| June 2 |
Delcath Systems Granted Third Orphan Drug Designation |
| June 2 |
Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL765, a Dual Inhibitor of PI3K and mTOR |
| June 2 |
Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis |
| June 2 |
Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain |
| June 2 |
Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO |
| June 2 |
Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer |
| June 2 |
New Data from Satraplatin Phase 3 Trial in Second-Line Castrate-Refractory Prostate Cancer Presented at 2009 ASCO Annual Meeting |
| June 2 |
Gloucester Pharmaceuticals Presents Positive Clinical Data for Romidepsin in CTCL and Further Preclinical Evidence of Synergism with Bortezomib at ASCO |
| June 2 |
GTx's Toremifene 80 Mg Increased Bone Mineral Density in Multiple Clinically Relevant Subpopulations of Prostate Cancer Patients on Androgen Deprivation Therapy |
| June 2 |
NeurogesX Receives FDA Orphan Drug Designation for Qutenza for Treatment of Postherpetic Neuralgia |
| June 2 |
New Clinical Data for Tesetaxel, a Leading Oral Taxane, Show Anticancer Activity and Acceptable Safety in Ongoing Study |
| June 2 |
Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients |
| June 2 |
Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting |
| June 2 |
Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting |
| June 2 |
Positive Results from Salix Pivotal Phase III Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE) Presented at Digestive Disease Week (DDW) |
| June 2 |
Pivotal Study Results: ChemGenex's Omacetaxine May Provide the First Viable Drug Treatment Option for Patients With a Highly Resistant Form of CML |
| June 2 |
Plexxikon Announces PLX4032 Phase 1 Data Showing Objective Responses in Metastatic Melanoma Patients |
| June 2 |
QLT Announces Positive Results from the Evaluation of Visudyne Combination Therapy |
| June 2 |
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting |
| June 2 |
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN Presented in Oral Session at DDW 2009 Conference |
| June 3 |
TransMolecular Presents New Data Highlighting the Anti-angiogenic and Tumor-targeting Properties of TM601 at ASCO Annual Meeting |
| June 3 |
New Data Suggest Treatment Regimens That Include ABRAXANE May Be Active in Treating Metastatic Melanoma |
| June 3 |
CombinatoRx Announces Positive Results for Aligned-Release Synavive |
| June 3 |
Positive Results from Pivotal Salix Phase III Study (Hepatic Encephalopathy) Presented at Meeting |
| June 3 |
DAZMedia Opens LA Social Media Practice |
| June 3 |
Access Pharmaceuticals Provides Update on ProLindac Phase 2 Ovarian Cancer Trial and Clinical Development Plan |
| June 3 |
Advaxis Receives FDA Response to Orphan Drug Filing |
| June 3 |
Generex Presents Positive Results of Phase 1 Prostate Cancer Vaccine Trial at the American Society of Clinical Oncology |
| June 3 |
New Clinical Data for Tesetaxel, a Leading Oral Taxane, Show Anticancer Activity and Acceptable Safety in Ongoing Study Responses Observed at Lower Doses |
| June 3 |
Genasense Combined with Temodar and Abraxane Shows Preliminary Evidence of High Response Rates and Extended Survival in Patients with Advanced Melanoma |
| June 3 |
Genasense Combined with Temodar and Abraxane Shows Preliminary Evidence of High Response Rates and Extended Survival in Patients with Advanced Melanoma |
| June 3 |
Data on VIVUS' Qnexa to be Presented During Two Podium Presentations at ADA Annual Meeting |
| June 3 |
GPC Biotech AG (DE) - New Data from Satraplatin Phase 3 Trial in Second-Line Castrate-Refractory Prostate Cancer Presented at 2009 ASCO Annual Meeting |
| June 3 |
FDA Forms Transparency Task Force |
| June 3 |
New Findings Demonstrate Potential Benefits of GATTEX (teduglutide) in Phase 3 Study of Patients with Short Bowel Syndrome |
| June 3 |
Newly Presented Data On Gaster Show Prevention Of Peptic Ulcers In Users Of Low-Dose Aspirin |
| June 3 |
Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI |
| June 3 |
PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice |
| June 3 |
ZIOPHARM Presents Positive Darinaparsin Clinical Data at ASCO's Prestigious Clinical Science Symposium |
| June 3 |
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment |
| June 3 |
Interim analysis confirms immunosafety of Rhucin |
| June 3 |
Oxford BioMedica Presents Updated TroVax Phase I/II and II Results at ASCO Annual Meeting |
| June 3 |
FDA MedWatch - Propylthiouracil (PTU) associated with risk of serious liver injury, including liver failure and death |
| June 3 |
TNFerade Phase III Data Presented at ASCO |
| June 3 |
Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables |
| June 3 |
Peregrine presents promising breast cancer data at ASCO |
| June 3 |
Inovio Biomedical Influenza DNA Vaccines Demonstrate Potential to Protect Against Newly Emerging Flu Strains with Pandemic Potential |
| June 4 |
EpiCept Releases New Data Demonstrating Long-Term Durability of Ceplene in Sustaining Leukemia-Free Survival |
| June 4 |
Trabedersen shows good safety, tolerability and promising survival in patients with pancreatic carcinoma, malignant melanoma and colorectoral carcinoma |
| June 4 |
EyeGate Pharma Announces That EGP-437 Improved Signs And Symptoms Of Dry Eye Syndrome In A Phase II Study |
| June 4 |
Positive Outcome Reached at 16 Weeks for Avexa's ATC Phase III Trial |
| June 4 |
ImmunoCellular Therapeutics Reports Additional Data from Promising Brain Cancer Clinical Trial |
| June 4 |
Stiefel Laboratories Reaps First Fruits of Barrier Acquisition With Completion of Pivotal Phase III Clinical Trial for 200 mg Hyphanox(TM) (Itraconazole) Tablet |
| June 5 |
Avandia Attorney Says Study Based on 'Useless Trick Science' |
| June 5 |
Single Dose Palonosetron Prevents Emesis Induced By Chemotherapy In Non Hodgkin's Lymphoma Patients |
| June 5 |
Tasigna shows rapid and deep responses in newly diagnosed patients with a form of chronic myeloid leukemia |
| June 5 |
PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans |
| June 5 |
Rolofylline Did Not Demonstrate Efficacy for Acute Heart Failure in Clinical Trial |
| June 5 |
ACTEMRA (tocilizumab) Studies to be Featured at the European League Against Rheumatism (EULAR) Congress |
| June 5 |
Access Pharmaceuticals Announces Publication of Thiarabine Combination Data |
| June 5 |
Memgen Reports Positive Results for ISF35 in High-Risk Chronic Lymphocytic Leukemia |
| June 5 |
Paclitaxel Poliglumex (OPAXIO Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer |
| June 5 |
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival |
| June 5 |
Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials |
| June 5 |
GlaxoSmithKline Consumer Healthcare Makes Agency Changes to Support Growth on Global Brands |
| June 8 |
Tranzyme Pharma to Present Multiple Applications of its Proprietary Drug Discovery Technology at the 21st American Peptide Society Symposium |
| June 8 |
Alnylam and Cubist Report Preliminary Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus |
| June 8 |
GTx Announces Ostarine (MK-2866) Clinical Trial Data to be Presented at ENDO 2009 |
| June 8 |
Alnylam to Webcast Conference Call to Discuss Preliminary Data from Phase II Study of ALN-RSV01 |
| June 8 |
Study Shows Consistent Use of Insulin Pump Therapy, Augmented with Continuous Glucose Monitoring, Results in Significant A1C Reductions |
| June 8 |
Update on Lu AA21004 Clinical Development Programme in Major Depressive Disorder |
| June 8 |
Research: Popular Diabetes Medications Associated with Increase in Bone Fractures |
| June 8 |
Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines |
| June 8 |
ChemGenex's Omacetaxine Shows Activity in Refractory CML |
| June 8 |
Potential Signals of Serious Risks/New Safety Information Identified from the Adverse Event Reporting System (AERS) between October - December 2008 |
| June 8 |
ChemGenex's Omacetaxine Kills Leukemic Stem Cells in Human CML Models |
| June 8 |
Impax Pharmaceuticals Announces Presentation of IPX066 Phase II Data at 13th International Congress of Parkinson's Disease and Movement Disorders |
| June 8 |
Initial Therapy with JANUMET (sitagliptin/metformin) Provided Significantly Greater Blood Sugar Lowering Compared to Metformin Alone in Patients with Type 2 Diabetes |
| June 8 |
Seattle Genetics Reports Data from SGN-35 Every Three Week Dosing Phase I Trial in Lymphoma |
| June 8 |
Dyax Presents Integrated Analysis of Phase 3 Data for DX-88 for Hereditary Angioedema |
| June 8 |
Halozyme's Phase 2 Insulin-PH20 Study Demonstrates Faster Insulin Absorption and Superior Glucose Control in Type 1 Diabetic Patients |
| June 8 |
Calistoga Pharmaceuticals Reports Additional Clinical Responses in Ongoing Clinical Trial of CAL-101, an Isoform-Selective PI3 Kinase Inhibitor, Under Evaluation in Patients with Hematologic Malignancies |
| June 8 |
Dapagliflozin Study Demonstrated Improved Glycemic Control In Type 2 Diabetes Patients Treated With High Doses of Insulin and Common Oral Anti-Diabetic Medicines |
| June 9 |
Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients |
| June 9 |
Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily |
| June 9 |
Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins) |
| June 9 |
Orexigen Therapeutics Presents Additional NB-302 Contrave Data at American Diabetes Association (ADA) 69th Scientific Sessions |
| June 9 |
Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk |
| June 9 |
Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association |
| June 9 |
Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association |
| June 9 |
ConjuChem Reports Data on PC-DAC: Exendin-4 and PC-Insulin at 2009 American Diabetes Association Meeting |
| June 9 |
AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer |
| June 9 |
Afinitor Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial |
| June 9 |
Abbott's TRILIPIX (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets |
| June 9 |
Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions |
| June 9 |
Talecris Biotherapeutics Receives Orphan Drug Designation for Plasmin (Human) to Treat Acute Peripheral Arterial Occlusion |
| June 9 |
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients |
| June 9 |
Celator Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress |
| June 9 |
Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections |
| June 9 |
Clinical Pharmacology Study With AZILECT (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity |
| June 9 |
Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients |
| June 9 |
Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting |
| June 9 |
Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009 |
| June 9 |
Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit |
| June 9 |
ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease |
| June 9 |
Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis |
| June 9 |
StemCells, Inc. Announces Positive Phase I Batten Trial Results |
| June 9 |
VIAject Presentations at ADA Meeting Highlight Drug's Mechanism of Absorption and Microvascular Effects |
| June 9 |
Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281 |
| June 9 |
Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study |
| June 9 |
The Lancet publishes direct comparison study between liraglutide and exenatide |
| June 9 |
MedThink Communications Wins Four Aster Awards in Healthcare Advertising Agency Competition |
| June 9 |
Transcept Pharmaceuticals Presents Data at SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies |
| June 9 |
Weber Shandwick Chosen By National Marrow Donor Program To Head Awareness Campaign |
| June 9 |
NicOx Publishes Results of the ZEST Phase 2 Study for Naproxcinod |
| June 9 |
Arete Therapeutics Reports Preclinical and Clinical Data at ADA |
| June 9 |
Seattle Genetics Presents Final Lintuzumab Phase I Clinical Data |
| June 9 |
Chandler Chicco Companies Announces New Brandtectonics Access US Offering |
| June 10 |
Amarin Announces Results from Exploratory Phase 2a Study of EN101 in Myasthenia Gravis |
| June 10 |
Response Rates of 58-74% With Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL |
| June 10 |
Orange Label Advertising Agency Recognized for its Healthcare Marketing and Branding Prowess |
| June 10 |
Nutra Pharma Announces Study Showing RPI-78 More Effective than Morphine in the Treatment of Moderate to Severe Pain |
| June 10 |
Avid Radiopharmaceuticals to Present Clinical Trial Advances in Molecular Imaging of Alzheimer's Disease, Parkinson's Disease and Diabetes |
| June 10 |
Genmab Announces Partial Clinical Hold on Zalutumumab Studies |
| June 10 |
InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting |
| June 10 |
Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride |
| June 10 |
Acceleron to Present ACE-031 Preclinical Study Results as Treatment for Loss of Muscle Mass and Function |
| June 10 |
Joint Statement on Atypical Antipsychotic Use in Children |
| June 10 |
Cline Davis & Mann Launches Brand Anatomy, a New Branding Division Focused Exclusively on Healthcare Clients |
| June 10 |
FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight |
| June 10 |
Presented at SLEEP 2009: New Controlled-Release Formulations of Proven Drug Being Developed for Middle-of-the-Night Awakening |
| June 10 |
Juvista European Phase 2 clinical trial |
| June 10 |
New Analyses Show Nasonex Is More Effective Than Loratadine For The Treatment Of Nasal Allergy Symptoms And At Least Comparable For Ocular Symptoms |
| June 10 |
Chandler Chicco Companies launches Brandtectonics Access |
| June 10 |
Data Demonstrate Aerius® (Desloratadine) Reduces Symptoms And Improves Quality Of Life In Patients With Persistent Allergic Rhinitis |
| June 10 |
Starting Antiretroviral Therapy Earlier Yields Better Clinical Outcomes |
| June 10 |
New Analysis Shows Efficacy of Simponi (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients |
| June 10 |
Newly Analyzed Data Show Daily Treatment With Nasonex Significantly Reduces Symptom Recurrence In Patients With Perennial Allergic Rhinitis |
| June 10 |
Two-Year Data Show Patients Receiving Simponi (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis |
| June 11 |
Aradigm Presents Phase 1 and Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Healthy Volunteers and Cystic Fibrosis Patients at the 32nd European Cystic Fibrosis Conference |
| June 11 |
Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA (Formerly LymphoStat-B) in Patients With Active Systemic Lupus Erythematosus |
| June 11 |
Genetic Variant Associated With Resistance To Chemotherapy Drug In Women With Breast Cancer |
| June 11 |
HRV phase IIa study achieves clinical proof-of-concept |
| June 11 |
New Versartis Data Demonstrates Potential for Monthly Dosing |
| June 11 |
Ardea Biosciences Announces Positive Interim Phase 2a Results for Lead Gout Drug, RDEA594 |
| June 11 |
Human Genome Sciences Reports Positive Long-Term Data For Benlysta (Formerly Lymphostat-B) In Patients With Active Systemic Lupus Erythematosus |
| June 11 |
Sanofi-aventis and Regeneron Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites |
| June 11 |
GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results at Endocrine Society Annual Meeting |
| June 11 |
New Data on Once-Daily Extended Release Pramipexole Presented at 13th International Congress of Parkinson's Disease and Movement Disorders (MDS) |
| June 11 |
Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options |
| June 11 |
Enobia Announces Positive Interim Clinical Results with ENB-0040 |
| June 11 |
Data Demonstrated ACTEMRA (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients |
| June 11 |
Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV) |
| June 11 |
Cannabis Science: Can Cannabis-Based Drugs Slow the H1N1 "Swine Flu" Pandemic? |
| June 11 |
Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin for Insomnia in Elderly Patients |
| June 11 |
Pfizer's Oral JAK-3 Inhibitor Demonstrates Statistically Significant Response For Patients with Rheumatoid Arthritis, New Phase 2 Studies Show |
| June 11 |
New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease |
| June 11 |
MabThera reduces progression of joint damage in rheumatoid arthritis when used as a first-line biologic |
| June 12 |
NicOx presents naproxcinod results in several posters at EULAR |
| June 12 |
Novartis successfully demonstrates capabilities of cell-based technology for production of A(H1N1) vaccine |
| June 12 |
Orencia (Abatacept) Demonstrates Consistent Safety And Effectiveness Over 7 Years |
| June 12 |
NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies |
| June 12 |
CombinatoRx Presents Full Data on Synavive Phase 2 Knee OA Trial at EULAR 2009 |
| June 15 |
Aegerion Pharmaceuticals Announces Interim Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Hepatic Safety Profile |
| June 15 |
MedWatch - Sirolimus (marketed as Rapamune):clinical trial suggests increased mortality in stable liver transplant patients after conversion from CNI-based immunosuppressive regimen to sirolimus |
| June 15 |
FDA Issues Public Health Advisory Regarding Levemir Insulin |
| June 15 |
Advaxis' Clinical Trial Survival Data Significantly Exceeds the National Cancer Institute's Median Survival Statistic |
| June 15 |
New Enbrel (etanercept) Data to be presented at EULAR |
| June 15 |
Successful phase II/III trial of new therapy for adrenal insufficiency |
| June 16 |
New Animal Study of Rexahn's Serdaxin Shows Drug's Promise to Treat Anxiety and Depression with Minimal Side Effects |
| June 16 |
Obecure Achieves Successful Results in Its Proof of Concept Clinical Study Evaluating the Ability of Histalean to Mitigate Weight Gain Associated With Olanzapine |
| June 16 |
New Study Shows Javelin Pharmaceutical's Dyloject Well-Tolerated in High-Risk Patients with Impaired Renal and Hepatic Function |
| June 16 |
Actemra study shows patients experienced a significant inhibition in the progression of structural joint damage |
| June 16 |
MedWatch - Stimulant Medication in Children with AD/HD - FDA Perspective on Study Data Published about Potential Risks of AD/HD Stimulant Medications |
| June 16 |
Celgene Announces Positive Top Line Data from Randomized Controlled Phase II Study of Apremilast in Psoriatic Arthritis |
| June 16 |
Wyeth Announces Holder Right to Surrender Convertible Debentures |
| June 16 |
QuantRx Announces FluoroPharma to Present Phase I Study Results of Novel Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) Tracer |
| June 16 |
ARYx Therapeutics Inc. Updates Progress with Tecarfarin EmbraceAC Study |
| June 16 |
Theratechnologies presents results at ENDO |
| June 16 |
Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily Infergen with Ribavirin in Hepatitis C Virus Treatment Failures |
| June 16 |
Two Newly-Published Scientific Papers Showed That the Steroid Used in Company's Iluvien Device Acted as Both a VEGF Inhibitor and Neuroprotectant |
| June 17 |
Aegerion Pharmaceuticals Announces Final Lomitapide (AEGR-733) Phase II Data |
| June 17 |
Compugen Transfers to The NASDAQ Capital Market |
| June 17 |
Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer |
| June 17 |
Somnia Anesthesia: 3rd Study Confirms Anesthesia Improves Outcomes in Colonoscopies |
| June 17 |
Pharming announces Euro 9 million debt reduction and continued equity financing with Ya Global |
| June 17 |
Phase II trial demonstrates Elacytarabine may increase survival threefold in patients with late-stage leukaemia |
| June 17 |
TransMolecular's 131I-TM601 Successfully Localizes to Multiple Tumor Types without Targeting Healthy Tissue |
| June 17 |
Spectrum Pharmaceuticals to Raise $10 Million from Institutional Investors at $5.83 Per Share, the Closing Bid Price on Friday, June 12, 2009 |
| June 17 |
Deltagen Reports 2009 First Quarter Financial Results |
| June 17 |
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 |
| June 17 |
Study Demonstrates Efficacy of Pitavastatin in Elderly Patients |
| June 17 |
S&P: Watson Pharmaceuticals Inc. $1.75 Billion Acquisition Of Arrow Pharmaceuticals Group Will Not Affect Ratings |
| June 17 |
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne combination therapy |
| June 17 |
OcuCure Therapeutics? Topical Vascular Targeting Agent Demonstrates Long Term Safety |
| June 17 |
Pulmo BioTech Inc. Announces Fund Raising Agreement with Moody Capital Solutions, Inc. |
| June 17 |
Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome |
| June 17 |
Pitavastatin Demonstrates Promise for Low Incidence of Drug-Drug Interaction |
| June 17 |
Pixantrone Overview in Non-Hodgkin's Lymphoma to be Presented at 2009 Pan Pacific Lymphoma Conference |
| June 17 |
NicOx: additional 24?hour blood pressure results for naproxcinod presented at the European Meeting on Hypertension |
| June 17 |
New prostate cancer imaging agent shows promise in identifying metasatic lesions more quickly and accurately vs. current compounds |
| June 17 |
Quest PharmaTech Announces First Quarter Results |
| June 18 |
Alnylam and Collaborators Present New Pre-Clinical Research Findings on RNAi Therapeutics Targeting PCSK9, a Genetically Validated Regulator of LDL Metabolism |
| June 18 |
CytRx's Tamibarotene Demonstrates Statistically Significant Anti-Tumor Activity in Animal Trial for Multiple Myeloma |
| June 18 |
Cefepime (marketed as Maxipime) Update of Ongoing Safety Review |
| June 18 |
Tianyin Pharmaceutical Co., Inc. Provides Fiscal 2010 Guidance |
| June 18 |
Spectrum Pharmaceuticals Receives $10 Million from Two Institutional Investors at $5.83 Per Share |
| June 19 |
Avir Green Hills: Excellent Preclinical Data on Novel Type of Intranasal H5N1 Influenza Vaccine ? Technology Also Suitable for Vaccination against Swine Flu |
| June 19 |
Cell Therapeutics on Preliminary List of Additions to Russell 3000 Index and Russell Global Index |
| June 19 |
AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule |
| June 19 |
Enzo Biochem Announces Record 2009 Fiscal Third Quarter Revenues |
| June 19 |
ADVENTRX Pharmaceuticals Announces Closing of Financing |
| June 19 |
Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia |
| June 19 |
Immunomedics Reports Updated Phase II Results With Radiolabeled Epratuzumab in Non-Hodgkin's Lymphoma |
| June 19 |
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia |
| June 19 |
Oculus Innovative Sciences Announces Preliminary Results From 40-Patient Feasibility Study for Treatment of Acne With Enhanced Microcyn Hydrogel Formulation |
| June 19 |
EpiCept Announces Pricing of Public Offering |
| June 19 |
AEterna Zentaris to Raise US$10 Million from Institutional Investors at US$1.88 Per Share |
| June 19 |
Impax Laboratories to be Added to Russell 3000® Index and NASDAQ Biotechnology Equal Weighted Index |
| June 22 |
ImmunoGen, Inc. Prices Public Offering of Common Stock |
| June 22 |
KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10-K |
| June 22 |
MedWatch - Cefepime: FDA determined that data review do not indicate a higher rate of death in cefepime-treated patients |
| June 22 |
FDA Issues Safety Communication about an Ongoing Review of Stimulant Medications Used in Children with ADHD |
| June 22 |
Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization |
| June 22 |
Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Therapy for Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) |
| June 22 |
Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx Gentamicin Topical for the Treatment and Prevention of Diabetic Foot Infections |
| June 22 |
Merrion Pharmaceuticals Announces Positive Phase IIB Study For Orazol Tablet Form of Zoledronate IV Infusion At ASCO Annual Meeting |
| June 22 |
Fitch: H1N1 (Swine Flu) - A Reminder That Trade Bans Negatively Affect Cash Flow & Credit Profiles |
| June 23 |
The Alliance for the Advancement of Adult Stem Cell Therapy and Research Announces Successful Treatment of End-Stage Heart Disease with Stem Cells |
| June 23 |
Compugen Announces Positive Therapeutic Effects of Novel Peptide in Animal Model of Inflammatory Bowel Disease |
| June 23 |
Oral Rivaroxaban Reduces Death/Stroke/Further Heart Attack For Patients After Heart Attack Or Unstable Angina |
| June 23 |
Brain cancer drug update confirms exquisite targeting & promising efficacy |
| June 23 |
New research highlights potential of novel alpha-pharmaceutical in targeting and killing breast cancer cells |
| June 23 |
Phase II trial demonstrates Elacytarabine may increase survival threefold in patients with late-stage leukaemia |
| June 23 |
Acucela's Novel Visual Cycle Modulator Demonstrates Promise as a Treatment for Dry Age-Related Macular Degeneration |
| June 24 |
Pro-Pharmaceuticals' Chief Scientist Published Articles in Three Prestigious Peer-Reviewed Journals |
| June 24 |
BioLineRx Announces New Results Confirming the Mode of Action of Its Anti-Psychotic Drug- BL-1020 |
| June 24 |
Osiris Therapeutics Reports Interim Data for COPD Stem Cell Study |
| June 24 |
Eclipsys Corporation and DrFirst Physician Honored with ?E-Prescriber of the Year? Award at the 4th Annual Surescripts Safe-Rx Ceremony |
| June 24 |
CTIA- The Wireless Association Forum: Medical and Policy Experts Agree Wireless Technology Makes Healthcare More Efficient, Effective and Patient-Focused |
| June 24 |
Spherix Announces Positive Phase 2 Study Results |
| June 25 |
Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors |
| June 25 |
New Data from CLARITY Study Presented at 19th ENS Meeting Show Rapid and Sustained MS Relapse Reduction for Cladribine Tablets |
| June 25 |
Mayo Clinic Researchers Highlight Prostate Cancer Study with Ipilimumab |
| June 25 |
CytRx to Present Statistically Significant Evidence of Arimoclomol's Ability to Protect Experimental Animals from the Effects of Hypoxia at the 2009 International Society on Oxygen Transport to Tissue Conference |
| June 25 |
Inotek Pharmaceuticals' Novel Glaucoma Candidate, INO-8875, Significantly Reduces Intraocular Pressure in Phase 1/2 Study |
| June 25 |
FDA Approves Generic Prescription-Only Version of Plan B Emergency Contraceptive for Women Ages 17 and Under |
| June 25 |
Afinitor and Sandostatin LAR Phase II Data Show Advanced Pancreatic NET Patients Remain Progression-Free for Nearly 17 Months |
| June 25 |
Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors |
| June 25 |
The Biomarkers Consortium Completes First Project to Show that Adiponectin is a Predictive Biomarker for Type 2 Diabetes |
| June 26 |
Clinical Studies Validate Cancer Gene Delivery Platform: Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival |
| June 28 |
Supportive Care In Cancer: Second Generation 5-Ht3 Antagonists Open New Perspectives In Emesis Prevention |
| June 28 |
Second U.S. Independent Laboratory Confirms that Oculus Innovative Sciences' Microcyn Technology Effective at Inactivating H1N1 Swine Flu |
| June 28 |
Generex's New Vaccine Technology Could Speed Flu Vaccine Availability |
| June 28 |
Published Study Shows Novel Compounds May Help Protect Against Respiratory Depression |
| June 28 |
iCo Therapeutics Positive Oral Amphotericin B Data Published in the Journal of Infectious Diseases |
| June 28 |
Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints |
| June 28 |
Drug May Prolong Survival in Melanoma Patients |
| June 28 |
Crucell Announces Positive Results of Phase II Rabies Monoclonal Antibody Combination Clinical Study in Philippines |
| June 28 |
Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy |
| June 28 |
Advanced Life Sciences' Restanza Shows 100% Survival In Confirmatory Anthrax Study |
| June 29 |
CytRx Reports Favorable Progress Update for Its Pivotal Phase 2 Clinical Trial with Tamibarotene as a Third-line Treatment for Acute Promyelocytic Leukemia |
| June 29 |
BioSante Pharmaceuticals Comments on Study Showing No Increased Risk of Breast Cancer in Women Using Testosterone for Low Libido |
| June 29 |
AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium |
| June 30 |
XenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients with Spasticity |
| June 30 |
Primary Endpoint Achieved in Phase III Clinical Trial of Epogin in Chemotherapy Induced Anemia |
| June 30 |
DuoCort: New chronotherapy for adrenal insufficiency |
| June 30 |
Inovio assesses vaccine against swine flu |
| June 30 |
Vical H1 Influenza Vaccine Delivers Robust Preclinical Results With 100% Response |
| June 30 |
Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia |
| June 30 |
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) |
| June 30 |
iMedicor Adds Pre-populated CV's to its HIPAA Compliant Portal Through Partnership with VitalsSM |
| June 30 |
MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants |
| June 30 |
New Data: Efficacy and Responder Analyses of Divigel (estradiol gel) 0.1 percent for the Treatment of Menopause |
| June 30 |
Santhera's FJORD Phase IIb Study Demonstrates Efficacy of JP-1730/Fipamezole for the Treatment of Dyskinesia in Parkinson's Disease |
| June 30 |
New Data Supports Significant Economic and Clinical Value of Menopur in IVF |
